Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?
Interview: CEO Says He Welcomes Scrutiny, Competition
Executive Summary
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.
You may also be interested in...
Inovio To Streamline COVID-19 Vaccine Program Under New CEO
The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.
Coronavirus Update: Inovio Looks Outside US To Continue Vaccine Development
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses
Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.